• 1. Aggregation-induced emission enhancement in halochalcones?
  Patricia A. A. M. Vaz,Jo?o Rocha,Artur M. S. Silva New J. Chem., 2016,40, 8198-8201
• 2. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 3. An interplay between electronic and structural effects on the photoluminescence decay mechanisms in LaPO4·nH2O:Tb3+ and LaPO4:Tb3+ single-crystal nanorods?
  M. T. Colomer,S. Díaz-Moreno,A. Tamayo,A. L. Ortiz J. Mater. Chem. C, 2018,6, 12643-12651
• 4. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 5. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Phenylpyrimidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Phenylpyrimidines

Comprehensive Overview of 4H-Pyrido[1,2-a]pyrimidin-4-one, 6-methyl-2-phenyl- (CAS No. 64194-18-9)

The compound 4H-Pyrido[1,2-a]pyrimidin-4-one, 6-methyl-2-phenyl- (CAS No. 64194-18-9) is a heterocyclic organic molecule that has garnered significant attention in pharmaceutical and materials science research. Its unique structure, featuring a fused pyrido-pyrimidinone core with methyl and phenyl substituents, makes it a valuable scaffold for drug discovery and functional material development. Researchers are particularly interested in its potential as a kinase inhibitor precursor, given the growing demand for targeted therapies in oncology and inflammatory diseases.

From a chemical perspective, 6-methyl-2-phenyl-4H-pyrido[1,2-a]pyrimidin-4-one exhibits interesting photophysical properties that have sparked investigations into its applications in organic electronics and fluorescent probes. The extended π-conjugation system in its molecular framework contributes to these characteristics, aligning with current trends in developing novel optoelectronic materials for display technologies and sensors. Recent studies have explored its potential as a building block for metal-organic frameworks (MOFs), particularly in the context of gas storage and separation applications.

The synthesis of CAS 64194-18-9 typically involves multi-step organic transformations, with researchers continuously optimizing routes to improve yield and purity. Modern synthetic approaches often employ microwave-assisted synthesis or flow chemistry techniques to enhance efficiency, reflecting the pharmaceutical industry's push toward greener and more sustainable manufacturing processes. Analytical characterization of this compound commonly utilizes HPLC-MS, NMR spectroscopy, and X-ray crystallography, with particular attention to its polymorphic forms given their potential impact on bioavailability in drug formulations.

In pharmacological research, the pyrido[1,2-a]pyrimidin-4-one scaffold has shown promise in modulating various biological targets. Structure-activity relationship (SAR) studies of 6-methyl-2-phenyl-4H-pyrido[1,2-a]pyrimidin-4-one derivatives have identified potent analogs with activity against protein kinases, phosphodiesterases, and G-protein coupled receptors. These findings are particularly relevant given the increasing focus on precision medicine and the need for novel therapeutic agents with improved selectivity profiles.

The commercial availability of 4H-Pyrido[1,2-a]pyrimidin-4-one, 6-methyl-2-phenyl- has expanded in recent years, with several specialty chemical suppliers offering it as a research chemical for drug discovery programs. Market analysis indicates growing demand from both academic institutions and pharmaceutical companies engaged in fragment-based drug design and medicinal chemistry optimization projects. Pricing trends reflect its status as a relatively specialized building block, with costs varying based on purity specifications and order quantities.

From a regulatory standpoint, CAS 64194-18-9 is not currently classified as a controlled substance in major pharmaceutical markets, though researchers should always verify local regulations before procurement. Proper handling procedures should be followed in laboratory settings, including the use of appropriate personal protective equipment (PPE) and adherence to standard chemical hygiene practices. Material Safety Data Sheets (MSDS) provided by manufacturers contain detailed information about safe handling and storage conditions.

Recent patent literature reveals growing intellectual property activity surrounding pyrido[1,2-a]pyrimidin-4-one derivatives, particularly in therapeutic areas such as cancer treatment, neurodegenerative disorders, and metabolic diseases. This trend underscores the compound's importance as a privileged structure in medicinal chemistry. Several pharmaceutical companies have included 6-methyl-2-phenyl-4H-pyrido[1,2-a]pyrimidin-4-one analogs in their development pipelines, with some candidates advancing to clinical trials.

Future research directions for 4H-Pyrido[1,2-a]pyrimidin-4-one, 6-methyl-2-phenyl- may explore its potential in proteolysis targeting chimeras (PROTACs) and other emerging drug modalities. The compound's ability to serve as a versatile synthetic intermediate positions it well for applications in DNA-encoded library technology and covalent inhibitor development. Additionally, its photophysical properties warrant further investigation for applications in bioimaging and theragnostic approaches.

For researchers seeking additional information about 64194-18-9, numerous scientific databases provide detailed physicochemical data, synthetic procedures, and biological activity profiles. The compound's growing importance in both pharmaceutical and materials science research ensures that new findings about its properties and applications continue to emerge in peer-reviewed literature and conference presentations.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)